The Immunology Core I was originally established as the Molecular Immunology Core with three subcores focused on humoral immunity, cellular immunity, and flow-based assays. The mission of this Core is to develop, refine, and provide by training and technology-transfer state-of-the-art immunological assays to evaluate and quantify humoral and cellular responses to support NIH-sponsored AIDS research and training. The assays, reagents, and training offered by the Core are designed to support basic, clinical, and translational research in the prevention, detection, and treatment of HIV infection and AIDS. During the last five years, this Immunology Core has significantly increased its user base, with an overall 3.9-fold increase in total users from 21 to 82, and a 5.4-fold increase in support of local users (60% of total) and a 2.8-fold increase in non-local users (40% of total). Since 2002, the Immunology Core has continuously worked to expand its impact by focusing on the training of investigators in the use of the Core's technologies. As an example of these activities, we developed a hands-on workshop entitled """"""""Research ELISA Assays: The Practical Guide"""""""" in Nairobi, Kenya, February 14-25, 2005. Highlights of research progress during the last five years have included studies on HIV Envelope tropism, Envelope variation and its relationship to the development of neutralizing antibodies (NAbs), the role of antibodies in perinatal transmission in nonhuman primates, examination of the role of IgG with ADCC activity in newborn macaques, hepatitis C-specific T cell responses and phenotypic analysis of liver NK T cells, gamma-delta T cell involvement in the viral immune control of chronic human herpesvirus-8 (HHV8) infection, epitope-specific T cell proliferation in HIV-infected subjects with long-term nonprogression, detailed examination of T cell responses to HIV-2, novel scaffold approaches to present HIV Envelope epitopes as vaccines, and support of translational studies. Over the next five years, we propose: (1) continuous development of state-of-the art assays within a more streamlined organization with two cores located in two, rather than three, locations;(2) the inclusion of a new Core Manager;(3) a redistributed budget to support a higher level of personnel to provide expanded services to a wider group of users;(4) linkages to a new Protein Core at the Seattle Biomedical Research Institute to obtain materials in a more cost-effective manner;and (5) a stronger focus on outreach, with training sessions for individual investigators and technical workshops for groups requesting services to transfer technology and reagents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-23
Application #
8080969
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
23
Fiscal Year
2010
Total Cost
$177,142
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Young, J; Smith, C; Teira, R et al. (2018) Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. HIV Med 19:132-142
Olwit, Connie; Mugaba, Maureen; Osingada, Charles Peter et al. (2018) Existence, triggers, and coping with chronic sorrow: a qualitative study of caretakers of children with sickle cell disease in a National Referral Hospital in Kampala, Uganda. BMC Psychol 6:50
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings. AIDS Care 30:954-962
Heffron, Renee; Mugo, Nelly; Hong, Ting et al. (2018) Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS 32:1707-1713
Pyra, Maria; Brown, Elizabeth R; Haberer, Jessica E et al. (2018) Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships. AIDS Behav :
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Edwards, Jessie K; Cole, Stephen R; Moore, Richard D et al. (2018) Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. Am J Epidemiol :
LaCourse, Sylvia M; Cranmer, Lisa M; Bekker, Adrie et al. (2018) Symptom screening for active tuberculosis in pregnant women living with HIV. Cochrane Database Syst Rev 2018:
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Wagner, Anjuli D; O?Malley, Gabrielle; Firdawsi, Olivia et al. (2018) Brief Report: Disclosure, Consent, Opportunity Costs, and Inaccurate Risk Assessment Deter Pediatric HIV Testing: A Mixed-Methods Study. J Acquir Immune Defic Syndr 77:393-399

Showing the most recent 10 out of 1275 publications